VCU Massey Cancer Center



Scientists target the tumor microenvironment to shut down liver cancer

Devanand Sarkar Portrait

Over the course of a decade, VCU Massey Cancer Center researcher Devanand Sarkar, Ph.D., has uncovered astounding new insights into the development and progression of liver cancer, identifying key genetic drivers and shedding light on unknown associations with obesity and inflammation. Now, he and his colleagues have set their sights on immune cells found in the liver called macrophages, and their findings could lead to novel treatment approaches.

Continue reading →

First-of-its-kind research models immune responses in cellular immunotherapies

In the Cellular Immunotherapy and Transplantation Program at Virginia Commonwealth University Massey Cancer Center, scientists are pursuing a cross-collaborative effort that could potentially change the way cellular immunotherapies such as stem cell transplantation and CAR T-cell therapies are performed. This grassroots research is funded primarily through VCU Massey pilot grants, and it is culminating in a first-of-its-kind body of work that provides a detailed quantitative view of how the immune system responds to cellular therapies.

Continue reading →

New drug combination disrupts leukemia cells in preclinical studies

Research conducted by scientists at VCU Massey Cancer Center found that a novel combination of drugs is effective against acute myeloid leukemia (AML) in preclinical models. The findings, recently published in the journal Cancer Research, could lead to new and improved treatments for AML and other hematologic malignancies.

Continue reading →

Study shows palliative care associated with shorter hospitalizations and reduced medical costs

Palliative care consultations administered within three days of admission are linked to shorter hospitalizations and significant cost savings for chronically ill adults, according to a large meta-analysis study involving researchers at VCU Massey Cancer Center.

Continue reading →

Experimental drug combined with radiation selectively kills brain tumors in pre-clinical studies

Image of a series of skull CT scans on the wall

A new study led by scientists at VCU Massey Cancer Center has shown that an experimental drug known as AZ32 selectively sensitizes brain tumors to radiation and significantly extends the survival of mouse models with human glioblastoma multiforme (GBM), the most common and deadly form of brain cancer. 

Continue reading →